RxDoctor Payments Data

Marie Obrien, DO

Rheumatology · Allentown, PANPI 1083836464

Payments from drug & device makers

$5,824in general payments, 2019–2025

Across 73 payments — averaging $79.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$4K
  • Amgen$1K
  • AbbVie$493
  • Aurinia Pharma U.S., Inc.$163
  • Novartis$146
  • Kala Pharmaceuticals, Inc.$93
  • plus $315 from 9 others

What the payments were for

  • Consulting fees$3,22555%
  • Travel & lodging$2204%
  • Food & beverage$2,34840%
  • Education$311%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,824 in reported general payments places this provider in the 55th percentile of 351 rheumatology providers in Pennsylvania.

See all rheumatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$243,217
Medicare patients
491
Services billed
16,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab42$420,742
Cosentyx Sensoready PenSecukinumab41$334,131
OtezlaApremilast46$216,310
Enbrel SureclickEtanercept21$194,037
Xeljanz XrTofacitinib Citrate29$166,492
KevzaraSarilumab33$134,723
RinvoqUpadacitinib16$100,674
Actemra ActpenTocilizumab29$100,133
Cosentyx Sensoready (2 Pens)Secukinumab12$90,678
SimponiGolimumab12$68,539
ProliaDenosumab14$22,983
Hydroxychloroquine Sulfate472$19,271
MethotrexateMethotrexate Sodium259$6,034
Gabapentin239$5,008
Azathioprine21$3,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Prolia$1,072$239,29360 claims
AbbVieRinvoq$493$100,67416 claims
Johnson & JohnsonSimponi$3,542$68,53912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 351 rheumatology providers in Pennsylvania.

Other rheumatology in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →